Business - Briefly   

Lupin pact with Baxter

MUMBAI, FEB. 28. Lupin has entered into an agreement with Baxter Healthcare Corporation, an U.S-based medical products company, wherein the latter will exclusively distribute the company's generic version of ceftriaxone sterile vials for injection in the U.S. Lupin intends to launch the product in the U.S. after the product patent expiry in July 2005, the pharma major said in a release here.

Lupin is the first and only company with an ANDA approval from the USFDA for ceftriaxone.

PTI

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary | Updates: Breaking News |

Stories in this Section

• Bharti Televenture's new initiatives
• IPCL issue raises Rs. 1,200 cr.
• India is entrepreneur driven, says Jaitley
• Hemogenomics centre in Bangalore
• Banks asked to use NBFCs for transport finance
• Dr. Reddy's loses to Pfizer in drug ruling
• Judge drops fraud charge against Martha Stewart
• Forex reserves exceed $107 b
• Lupin pact with Baxter
• Unichem to set up U.S. subsidiary

Copyright © 2004, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu